Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,787 shares of the biopharmaceutical company’s stock after purchasing an additional 599 shares during the period. Valeo Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $938,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Keudell Morrison Wealth Management boosted its position in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Keudell Morrison Wealth Management now owns 695 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 110 shares during the period. Marietta Wealth Management LLC boosted its position in Regeneron Pharmaceuticals by 6.2% during the 2nd quarter. Marietta Wealth Management LLC now owns 11,451 shares of the biopharmaceutical company’s stock worth $6,012,000 after acquiring an additional 673 shares during the period. Checchi Capital Advisers LLC boosted its position in Regeneron Pharmaceuticals by 7.3% during the 2nd quarter. Checchi Capital Advisers LLC now owns 732 shares of the biopharmaceutical company’s stock worth $384,000 after acquiring an additional 50 shares during the period. Willner & Heller LLC boosted its position in Regeneron Pharmaceuticals by 18.7% during the 2nd quarter. Willner & Heller LLC now owns 469 shares of the biopharmaceutical company’s stock worth $246,000 after acquiring an additional 74 shares during the period. Finally, Quent Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 9.8% in the second quarter. Quent Capital LLC now owns 438 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 39 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.4%

REGN stock opened at $583.24 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,024.36. The firm has a 50 day simple moving average of $573.16 and a 200 day simple moving average of $566.16. The firm has a market cap of $61.82 billion, a PE ratio of 14.70, a P/E/G ratio of 1.87 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 EPS. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on REGN shares. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a research note on Monday, August 4th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target for the company. in a research note on Friday, August 1st. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Guggenheim upped their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.